RECRUITING

Role of Race in Nutritional Approach in Men on ADT

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

There is a well-documented association between androgen deprivation therapy (ADT) and cardiovascular morbidity. A majority of men on ADT gain weight contributing to an increase in cardiovascular risk factors (CVRFs) and cardiovascular morbidity. Dietary intervention combined with exercise have shown success in reducing weight/fat mass and improving cardiovascular risk factors (CVRF). There is little data on whether African American men would respond to diet and exercise interventions differently from non-Hispanic white men. We will conduct a pilot, controlled two-phase intervention study stratified by race to investigate the following objectives: 1. Compare effect of a hypocaloric, anti-inflammatory diet on changes in fat mass between African- American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy. 2. Compare effect of a hypocaloric, anti-inflammatory diet on changes in cardiovascular risk factors (body weight, lean body mass, waist-to-height ratio, blood pressure, lipids and HbA1C) and inflammatory markers (hs-CRP and cytokines) between African-American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy. 3. Compare effect of a hypocaloric, anti-inflammatory diet on changes in cancer-related fatigue and quality of life between African-American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy. We will enroll 35 African American and 35 non-Hispanic white men with prostate cancer undergoing ADT therapy. In phase 1, after baseline assessment, men will consume their habitual diet and continue their habitual activity level for 3 months. During phase 2, participants will be instructed to consume a hypocaloric (-500 kcal), anti- inflammatory diet and walk for 1 hour on 3 days per week for 3 months. At baseline, after phase 1 and 2 primary outcome (fat mass) and secondary outcomes (CVRF and inflammatory markers) and tertiary outcomes (cancer-related fatigue and quality of life) will be determined.

Official Title

Contribution of Race to Nutritional Approach to Lower Cardiovascular Risk Factors in Men Undergoing Androgen Deprivation Therapy

Quick Facts

Study Start:2024-03-28
Study Completion:2025-11-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06682390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \>12 months on ADT
  2. * Expected continuation of ADT for \>6 months upon initiation of study procedures
  3. * Serum testosterone \<50 ng/dL
  4. * BMI \>25
  5. * Age \>18 years old
  6. * African American and Non-Hispanic white males
  7. * Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent
  1. * Life expectancy \< 1 year
  2. * Females
  3. * Radiation or chemotherapy treatment
  4. * History of diabetes or serious medical condition including uncontrolled hypertension, liver, kidney, and cardiovascular disease
  5. * Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator
  6. * Any subject who currently uses tobacco products
  7. * Any use of \>20 g of alcohol per day
  8. * Any subject who is unable or unwilling to comply with the study protocol
  9. * Any subject who is unable to provide consent

Contacts and Locations

Study Contact

Tatiana Diacova, PhD, MS, RDN
CONTACT
310-825-8499
tdiacova@mednet.ucla.edu

Principal Investigator

Zhaoping Li, MD, PhD
PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Matthew Rettig, MD
PRINCIPAL_INVESTIGATOR
Greater Los Angeles Division of Veterans Affairs, Los Angeles, California 90073

Study Locations (Sites)

Greater Los Angeles Division of Veterans Affairs
Los Angeles, California, 90073
United States
UCLA Health 200 Medical Plaza
Los Angeles, California, 90095
United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

  • Zhaoping Li, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, Los Angeles
  • Matthew Rettig, MD, PRINCIPAL_INVESTIGATOR, Greater Los Angeles Division of Veterans Affairs, Los Angeles, California 90073

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-28
Study Completion Date2025-11-29

Study Record Updates

Study Start Date2024-03-28
Study Completion Date2025-11-29

Terms related to this study

Keywords Provided by Researchers

  • ADT
  • cardiovascular risk factors

Additional Relevant MeSH Terms

  • Prostate Cancer Metastatic Disease